Serum CCL2 is associated with visceral adiposity but not fibrosis in patients with Non-alcoholic Fatty Liver Disease (NAFLD).
Conclusion. Circulating CCL2 and FABP2 are associated with NAFLD co-morbidities, but not liver disease progression in patients with NAFLD.
Source: Digestive Diseases - Category: Gastroenterology Source Type: research
More News: Alcoholism | Cancer & Oncology | Carcinoma | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Gastroenterology | Heart | Hepatocellular Carcinoma | Insulin | Liver | Liver Cancer | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Urology & Nephrology